Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FBQAG
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,474
Award facts
- Contract value 100% obligated
- $17,474.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $17,474.40 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Xolair 300 mg/2 ml auto-injector vials. This firm fixed-price delivery order, issued on January 27, 2026, with an ultimate completion date of February 18, 2026, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The delivery order falls under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial contracting activity through the Defense Logistics Agency's Medical Supply Chain division. The company's product portfolio encompasses branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, including oncology treatments, immunosuppressants, and emergency medications. The company's single-award IDC under the PPV-G GEN V program, designated as contract SPE2DR and valued at $499,999,999, extends through December 31, 2036, positioning DMS Pharmaceutical Group as a regional prime vendor contractor supporting recurring medical supply needs of military healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FBQAG?
SPE2DR26FBQAG was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 27, 2026.
How much is contract SPE2DR26FBQAG worth?
The government has obligated $17,474 on SPE2DR26FBQAG.
Is contract SPE2DR26FBQAG an order under another contract?
Yes. SPE2DR26FBQAG is a delivery order under SPE2DR25D9304, an indefinite delivery contract.
Was contract SPE2DR26FBQAG competed?
The extent of competition for SPE2DR26FBQAG was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award